

IMPORTANT:

Hong Kong Exchanges and Clearing Limited (“**HKEx**”), The Stock Exchange of Hong Kong Limited (“**SEHK**”), Hong Kong Securities Clearing Company Limited (“**HKSCC**”) and the Securities and Futures Commission (“**SFC**”) take no responsibility for the contents of this Announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement.

SFC authorisation is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

This document is important and requires your immediate attention. If you are in any doubt about the contents of this Announcement, you should seek professional advice. Investment involves risks which may result in significant loss as there is no guarantee on investment returns. Past performance is not indicative of future returns. Please refer to the offering documents (including the risk factors stated therein) for details before making any investment decision.

The Manager accepts full responsibility for the accuracy of the information contained in this Announcement as at the date of its publication and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, there are no other facts the omission of which would make any statement misleading.

C-Shares CSI Healthcare Index ETF (the “Sub-Fund”)

(A sub-fund of CHINA UNIVERSAL INTERNATIONAL ETF SERIES, a Hong Kong umbrella unit trust authorized under Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)

**RMB Counter Stock Code: 83132
HKD Counter Stock Code: 03132**

Announcement Audited Annual Report 2017

We are pleased to inform you that the audited annual report of the Sub-Fund for the period from 1 January 2017 to 31 December 2017 (the “**Annual Report**”) is now available on the Manager’s website at www.99fund.com.hk¹ and the HKEx’s website at www.hkexnews.hk.

Should you wish to obtain a printed copy of the Annual Report, you may visit the Manager’s office at Room 3710-3711, 37/F, Two International Finance Centre, 8 Finance Street, Central, Hong Kong during office hours (8:30 a.m. to 5:30 p.m., Mondays to Fridays).

Should there be any queries concerning the above, please contact the Manager at (852) 3983 5600.

China Universal Asset Management (Hong Kong) Company Limited
匯添富資產管理（香港）有限公司

30 April 2018

¹ This website has not been reviewed by the Securities and Futures Commission.

重要提示：

香港交易及結算所有限公司（「香港交易所」）、香港聯合交易所有限公司（「聯交所」）、香港中央結算有限公司（「香港結算」）及證券及期貨事務監察委員會（「證監會」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並表明不會就本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

證監會的認可並不代表證監會對計劃作出推薦或認許，亦不代表其對計劃的商業利弊或其表現作出保證。這不表示計劃適合所有投資者或認許計劃適合任何特定投資者或投資者類別。

此乃重要文件，務須閣下即時垂注。閣下如對本公告的內容有任何疑問，閣下應尋求專業意見。投資涉及風險，由於概不保證投資回報，故可能導致重大損失。過往業績不代表將來表現。投資者在作出任何投資決定前，請參考銷售文件(包括當中所載之風險因素)以便獲取詳細資料。

基金經理就本公告於刊發日期所載資料的準確性承擔全部責任，並在作出一切合理查詢後確認，據其所知及所信，並無遺漏致使任何陳述有所誤導的任何其他事實。

添富共享中証醫藥衛生指數ETF （「子基金」）

（匯添富國際ETF系列的子基金。匯添富國際ETF系列是根據香港《證券及期貨條例》（第571章）第104條獲認可的香港傘子單位信託）

人民幣櫃台股份代號：83132

港幣櫃台股份代號：03132

公告

2017年經審核年度報告

我們欣然通知閣下子基金由2017年1月1日至2017年12月31日期間的經審核年度報告（「年度報告」）現於基金經理之網站www.99fund.com.hk²及香港交易所之網站www.hkexnews.hk刊登。

閣下亦可於辦公時間（星期一至星期五上午8時30分至下午5時30分）親臨基金經理的辦事處(地址為香港中環金融街8號國際金融中心二期3710-11室)索取該年度報告之印刷本。

如有任何查詢，請致電 (852) 3983 5600 與基金經理聯絡。

匯添富資產管理（香港）有限公司
China Universal Asset Management (Hong Kong) Company Limited

2018年4月30日

²本網站並未經證監會審閱。